Table 3 Most common (occurring in ≥15% of patients) TEAEs by baseline renal function and treatment arm.
n (%) | eGFR <60 mL/min/1.73 m2 | eGFR ≥60 mL/min/1.73 m2 | ||
|---|---|---|---|---|
Isa-Pd (n = 54) | Pd (n = 47) | Isa-Pd (n = 86) | Pd (n = 94) | |
Any | 54 (100.0) | 47 (100.0) | 85 (98.8) | 91 (96.8) |
Infections | ||||
Upper respiratory tract infection | 16 (29.6) | 6 (12.8) | 27 (31.4) | 19 (20.2) |
Bronchitis | 11 (20.4) | 2 (4.3) | 21 (24.4) | 9 (9.6) |
Pneumonia | 16 (29.6) | 12 (25.5) | 15 (17.4) | 14 (14.9) |
Blood and lymphatic system disorders | ||||
Neutropenia | 24 (44.4) | 19 (40.4) | 43 (50.0) | 29 (30.9) |
Thrombocytopenia | 8 (14.8) | 8 (17.0) | 10 (11.6) | 9 (9.6) |
Febrile neutropenia | 9 (16.7) | 3 (6.4) | 8 (9.3) | 0 |
Respiratory, thoracic and mediastinal disorders | ||||
Dyspnea | 5 (9.3) | 5 (10.6) | 16 (18.6) | 9 (9.6) |
Gastrointestinal disorders | ||||
Diarrhea | 15 (27.8) | 14 (29.8) | 22 (25.6) | 14 (14.9) |
Constipation | 7 (13.0) | 8 (17.0) | 16 (18.6) | 17 (18.1) |
Nausea | 6 (11.1) | 7 (14.9) | 16 (18.6) | 7 (7.4) |
Musculoskeletal and connective tissue disorders | ||||
Back pain | 14 (25.9) | 7 (14.9) | 11 (12.8) | 15 (16.0) |
General disorders and administration site conditions | ||||
Fatigue | 10 (18.5) | 13 (27.7) | 16 (18.6) | 18 (19.1) |
Peripheral edema | 5 (9.3) | 6 (12.8) | 15 (17.4) | 10 (10.6) |
Pyrexia | 12 (22.2) | 10 (21.3) | 8 (9.3) | 9 (9.6) |
Asthenia | 6 (11.1) | 11 (23.4) | 12 (14.0) | 15 (16.0) |
Procedural complications | ||||
Infusion-related reaction | 18 (33.3) | 1 (2.1) | 34 (39.5) | 1 (1.1) |
